(6-Methoxy-2-cyclopentylbenzo[b]thien-3-yl)[4-[2-(1-piperidinyl)ethoxy]phenyl]methanone | 150797-48-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (6-Methoxy-2-cyclopentylbenzo[b]thien-3-yl)[4-[2-(1-piperidinyl)ethoxy]phenyl]methanone
• 英文别名: (2-Cyclopentyl-6-methoxy-1-benzothiophen-3-yl)-[4-(2-piperidin-1-ylethoxy)phenyl]methanone
• CAS: 150797-48-1
• 化学式: C₂₈H₃₃NO₃S
• 分子量: 463.641
• InChiKey: DRNIAJXRIVAJOW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.8
• 重原子数：
  33
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  67
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (6-Methoxy-2-cyclopentylbenzo[b]thien-3-yl)[4-[2-(1-piperidinyl)ethoxy]phenyl]methanone 在 三乙基硅烷 、 lithium aluminium tetrahydride 、 三氯化铝 、 三氟乙酸 、 乙硫醇 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 2-Cyclopentyl-3-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-benzo[b]thiophen-6-ol
  参考文献：
  名称：

  Synthesis and pharmacology of 2-alkyl raloxifene analogs

  摘要：

  A series of 2-alkyl and 2-cycloalkyl raloxifene analogs have been prepared and evaluated in both in vitro and in vivo models of estrogen/antiestrogen activity. In particular, the 2-cyclohexyl analogs show promise as potent selective estrogen-receptor modulators (SERMs).

  DOI：

  10.1016/0960-894x(95)00575-e
• 作为产物：
  描述：

  6-甲氧基-N,N-二甲基苯并[b]噻吩-2-胺 以 四氢呋喃 、 氯苯 为溶剂， 反应 10.5h， 生成 (6-Methoxy-2-cyclopentylbenzo[b]thien-3-yl)[4-[2-(1-piperidinyl)ethoxy]phenyl]methanone
  参考文献：
  名称：

  Structure−Activity Relationships of Selective Estrogen Receptor Modulators:  Modifications to the 2-Arylbenzothiophene Core of Raloxifene

  摘要：

  The 8-arylbenzothiophene raloxifene, 1, is a selective estrogen receptor modulator which is currently under clinical evaluation for the prevention and treatment of postmenopausal osteoporosis. A series of raloxifene analogs which contain modifications to the 2-arylbenzothiophene core have been prepared and evaluated for the ability to bind to the estrogen receptor and inhibit MCF-7 breast cancer cell proliferation in vitro. Their ability to function as tissue-selective estrogen agonists in vivo has been assayed in a short-term, ovariectomized (OVX) rat model with end points of serum cholesterol lowering, uterine weight gain, and uterine eosinophil peroxidase activity. These studies have demonstrated that (1) the 6-hydroxy and, to a lesser extent, the 4'-hydroxy substituents of raloxifene are important for receptor binding and in vitro activity, (2) small, highly electronegative 4'-substituents such as hydroxy, fluoro, and chloro are preferred both in vitro and in vivo, (3) increased steric bulk at the 4'-position leads to increased uterine stimulation in, vivo, and (4) additional substitution of the 2-aryl moiety is tolerated while additional substitution at the 4-, 5-, or 7-position of the benzothiophene results in reduced biological activity. In addition, compounds in which the 2-aryl group is replaced by alkyl, cycloalkyl, and naphthyl substituents maintain a profile of in vitro and in vivo biological activity qualitatively similar to that of raloxifene. Several novel structural variants including 2-cyclohexyl, 2-naphthyl, and 6-carbomethoxy analogs also demonstrated efficacy in preventing bone loss in a chronic OVX rat model of postmenopausal osteopenia, at doses of 0.1-10 mg/kg.

  DOI：

  10.1021/jm9606352

文献信息

• NOVEL BENZOTHIOPHENE DERIVATIVE
  申请人：TEIKOKU HORMONE MFG. CO., LTD.

  公开号：EP0641791A1

  公开（公告）日：1995-03-08

  A benzothiophene derivative represented by general formula (I) or a salt thereof, which has an excellent antiestrogenic activity and is useful for treating breast cancer, endometrial cancer, endometriosis, mastopathy, and so forth. This compound is characterized in that the 2-position, i.e. substituent R², of the benzothiophene ring is substituted by a halogen atom, a lower alkyl group, or a cycloalkyl or cycloalkenyl group which may be substituted by a lower alkyl, hydroxy, acyloxy or oxo.

  一种由通式(I)代表的苯并噻吩衍生物或其盐，具有优异的抗雌激素活性，可用于治疗乳腺癌、子宫内膜癌、子宫内膜异位症、乳腺病等。该化合物的特征在于苯并噻吩环的 2-位，即取代基 R² 被卤原子、低级烷基或环烷基或环烷烯基所取代，而环烷基或环烷烯基可被低级烷基、羟基、酰氧基或氧代所取代。
• US5472962A
  申请人：——

  公开号：US5472962A

  公开（公告）日：1995-12-05
• Structure−Activity Relationships of Selective Estrogen Receptor Modulators:  Modifications to the 2-Arylbenzothiophene Core of Raloxifene
  作者：Timothy A. Grese、Stephen Cho、Don R. Finley、Alexander G. Godfrey、Charles D. Jones、Charles W. Lugar、Michael J. Martin、Ken Matsumoto、Lewis D. Pennington、Mark A. Winter、M. Dee Adrian、Harlan W. Cole、David E. Magee、D. Lynn Phillips、Ellen R. Rowley、Lorri L. Short、Andrew L. Glasebrook、Henry U. Bryant

  DOI：10.1021/jm9606352

  日期：1997.1.1

  The 8-arylbenzothiophene raloxifene, 1, is a selective estrogen receptor modulator which is currently under clinical evaluation for the prevention and treatment of postmenopausal osteoporosis. A series of raloxifene analogs which contain modifications to the 2-arylbenzothiophene core have been prepared and evaluated for the ability to bind to the estrogen receptor and inhibit MCF-7 breast cancer cell proliferation in vitro. Their ability to function as tissue-selective estrogen agonists in vivo has been assayed in a short-term, ovariectomized (OVX) rat model with end points of serum cholesterol lowering, uterine weight gain, and uterine eosinophil peroxidase activity. These studies have demonstrated that (1) the 6-hydroxy and, to a lesser extent, the 4'-hydroxy substituents of raloxifene are important for receptor binding and in vitro activity, (2) small, highly electronegative 4'-substituents such as hydroxy, fluoro, and chloro are preferred both in vitro and in vivo, (3) increased steric bulk at the 4'-position leads to increased uterine stimulation in, vivo, and (4) additional substitution of the 2-aryl moiety is tolerated while additional substitution at the 4-, 5-, or 7-position of the benzothiophene results in reduced biological activity. In addition, compounds in which the 2-aryl group is replaced by alkyl, cycloalkyl, and naphthyl substituents maintain a profile of in vitro and in vivo biological activity qualitatively similar to that of raloxifene. Several novel structural variants including 2-cyclohexyl, 2-naphthyl, and 6-carbomethoxy analogs also demonstrated efficacy in preventing bone loss in a chronic OVX rat model of postmenopausal osteopenia, at doses of 0.1-10 mg/kg.
• Synthesis and pharmacology of 2-alkyl raloxifene analogs
  作者：Timothy A. Grese、Stephen Cho、Henry U. Bryant、Harlan W. Cole、Andrew L. Glasebrook、David E. Magee、D.Lynn Phillips、Ellen R. Rowley、Lorri L. Short

  DOI：10.1016/0960-894x(95)00575-e

  日期：1996.1

  A series of 2-alkyl and 2-cycloalkyl raloxifene analogs have been prepared and evaluated in both in vitro and in vivo models of estrogen/antiestrogen activity. In particular, the 2-cyclohexyl analogs show promise as potent selective estrogen-receptor modulators (SERMs).